UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   December 20, 2010

MedQuist Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

     
New Jersey 0-19941 22-2531298
_____________________
(State or other jurisdiction 		_____________
(Commission 		______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
1000 Bishops Gate Boulevard, Suite 300, Mount Laurel, New Jersey   08054-4632
_________________________________
(Address of principal executive offices) 		  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   856.206.4000

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07 Submission of Matters to a Vote of Security Holders.

The 2010 Annual Meeting of Shareholders of MedQuist Inc. (“MedQuist”) was held on December 20, 2010 (the “Annual Meeting”). At the Annual Meeting, the sole matter submitted to a vote of the holders of MedQuist’s common stock was a proposal to elect eight directors nominated by MedQuist’s Board of Directors.

Each of the eight nominees were elected as directors to hold office for a one-year term or until his successor is duly elected and qualified, with the following voting results:

                 
Director Nominee   Votes For   Votes Withheld
Robert Aquilina
    29,126,862       1,169,130  
Frank Baker
    29,058,603       1,237,389  
Peter E. Berger
    29,056,203       1,239,789  
John F. Jastrem
    30,246,481       49,511  
Colin J. O’Brien
    30,247,084       48,908  
Warren E. Pinckert II
    30,227,079       68,913  
Michael Seedman
    29,056,203       1,239,789  
Andrew E. Vogel
    30,241,251       54,741  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    MedQuist Inc.
          
December 27, 2010   By:   /s/ Mark R. Sullivan
       
        Name: Mark R. Sullivan
        Title: General Counsel, Chief Compliance Officer & Secretary
Medquist (NASDAQ:MEDQ)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 Medquist 차트를 더 보려면 여기를 클릭.
Medquist (NASDAQ:MEDQ)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 Medquist 차트를 더 보려면 여기를 클릭.